Literature DB >> 3892439

The problem of drug resistance in malaria.

W Peters.   

Abstract

The resistance in human malaria is mainly of practical importance in relation to Plasmodium falciparum. Strains resistant not only to chloroquine but also to dihydrofolate reductase inhibitors, and even to potentiating combinations of these with sulphonamides or sulphones, are appearing in an ever increasing geographical area which now includes tropical Africa and India. Few new drugs are available or foreseen for the near future, mefloquine and artemisinine being the leading contenders. It is vital that all measures possible should be taken to protect such new compounds, their deployment in the form of judiciously selected combinations with other antimalarials being an essential procedure that should be followed. Drugs in new chemical classes and with different modes of action are still urgently needed. Reliance should not be placed on drugs alone to control malaria on a community basis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3892439     DOI: 10.1017/s003118200005232x

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  21 in total

1.  QSAR for anti-malarial activity of 2-aziridinyl and 2,3-bis(aziridinyl)-1,4-naphthoquinonyl sulfonate and acylate derivatives.

Authors:  Mohamed Zahouily; Mohamed Lazar; Abdelhakim Elmakssoudi; Jamila Rakik; Sanaa Elaychi; A Rayadh
Journal:  J Mol Model       Date:  2005-12-09       Impact factor: 1.810

Review 2.  Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Authors:  Carol Hopkins Sibley; Ric N Price
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-20       Impact factor: 4.077

3.  Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with alpha-difluoromethylornithine cure murine malaria.

Authors:  A J Bitonti; J A Dumont; T L Bush; M L Edwards; D M Stemerick; P P McCann; A Sjoerdsma
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand.

Authors:  A L Fontanet; D B Johnston; A M Walker; W Rooney; K Thimasarn; D Sturchler; M Macdonald; M Hours; D F Wirth
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

5.  In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism.

Authors:  S A Queen; D L Jagt; P Reyes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene.

Authors:  D M Henderson; C D Sifri; M Rodgers; D F Wirth; N Hendrickson; B Ullman
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

Review 7.  Antimalarial drugs. An update.

Authors:  D C Warhurst
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

Review 8.  Combination therapy for malaria: the way forward?

Authors:  François Nosten; Philippe Brasseur
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Pharmacokinetics of quinine in African patients with acute falciparum malaria.

Authors:  C P Babalola; O O Bolaji; F A Ogunbona; A Sowunmi; O Walker
Journal:  Pharm World Sci       Date:  1998-06

10.  Reversed siderophores act as antimalarial agents.

Authors:  A Shanzer; J Libman; S D Lytton; H Glickstein; Z I Cabantchik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.